Curasight products

Curasight`s uTRACE is a uPAR-PET imaging and diagnostics technology. It is used to find, visualise, and predict whether a cancer is aggressive and if so, how it should be treated. uTRACE has been tested on over 400 patients in several cancer forms and proven to be safe.

Curasight`s uTREAT is new type of targeted radiation therapy, targeting and irradiating the cancer cells and almost not healthy tissue. By injecting a substance that seeks all cancer cells, including the metastases that are far away from the primary tumour, this offers a personalised and tailored therapy to each patient.

Curasight has developed a novel and innovative Theranostics platform for improved cancer diagnose and treatment. The combination of using targeted radionuclide therapy to treat cancer, and a non-invasive PET imaging for diagnosing and monitoring, is known as Theranostics (Therapy + Diagnostics = Theranostics). Curasight’s solution combines the technologies uTREAT® (targeted radionuclide therapy) and uTRACE® (based on non-invasive PET imaging). Both technologies target uPAR which is why Curasight’s solution is called uPAR Theranostics.